Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in... Read More
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and e... Read More
U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07747662) titled 'Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study' on ... Read More
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascimi... Read More
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with ... Read More
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy v... Read More
U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07747207) titled 'PULSTA TPV Observational Study' on July 30. Brief Summary: The purpose of the study is to d... Read More
U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07747285) titled 'POSH-Ex: Physiotherapist-Led Telerehabilitation Exercise Programme for Postpartum Sexual Hea... Read More
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel... Read More
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adj... Read More